The studies behind the pages

I get more from a study when I know what I am looking for before opening it. The participant group, comparison and measured outcome usually matter more than the most dramatic phrase in a summary. An animal experiment, a human trial and a medicine label also do different jobs.

A DOI is a permanent publication identifier. Trial names can sound opaque; the underlying questions are usually concrete: weight, heart events, deep fat or desire. I prefer to approach a paper with that question in mind.

1. Once-Weekly Semaglutide in Adults with Overweight or Obesity

   N Engl J Med, 2021.

   DOI 10.1056/NEJMoa2032183

2. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

   N Engl J Med, 2023.

   DOI 10.1056/NEJMoa2307563

3. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes

   N Engl J Med, 2024.

   DOI 10.1056/NEJMoa2403347

4. Safety of Semaglutide

   Front Endocrinol (Lausanne), 2021.

   DOI 10.3389/fendo.2021.645563

5. Semaglutide lowers body weight in rodents via distributed neural pathways

   JCI Insight, 2020.

   DOI 10.1172/jci.insight.133429

6. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity

   N Engl J Med, 2025.

   DOI 10.1056/NEJMoa2416394

7. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

   N Engl J Med, 2021.

   DOI 10.1056/NEJMoa2107519

8. Tirzepatide Once Weekly for the Treatment of Obesity

   N Engl J Med, 2022.

   DOI 10.1056/NEJMoa2206038

9. Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis.

   Front Endocrinol (Lausanne), 2023.

   DOI 10.3389/fendo.2023.1214334

10. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept

    Mol Metab, 2018.

    DOI 10.1016/j.molmet.2018.09.009

11. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial

    JAMA, 2014.

    DOI 10.1001/jama.2014.8334

12. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation

    AIDS, 2008.

    DOI 10.1097/QAD.0b013e32830a5058

13. Tesamorelin - LiverTox: Clinical and Research Information on Drug-Induced Liver Injury

    NCBI Bookshelf (NIH), 2018.

    https://www.ncbi.nlm.nih.gov/books/NBK548730/

14. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing

    Curr Rev Musculoskelet Med, 2025.

    DOI 10.1007/s12178-025-09990-7

15. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study

    Altern Ther Health Med, 2025.

    https://pubmed.ncbi.nlm.nih.gov/40131143/

16. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation

    J Mol Med (Berl), 2017.

    DOI 10.1007/s00109-016-1488-y

17. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs

    Front Pharmacol, 2022.

    DOI 10.3389/fphar.2022.1026182

18. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials

    Obstet Gynecol, 2019.

    DOI 10.1097/AOG.0000000000003500

19. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder

    Obstet Gynecol, 2019.

    DOI 10.1097/AOG.0000000000003514

20. Melanocortin 4 receptor agonism enhances sexual brain processing in women with hypoactive sexual desire disorder

    J Clin Invest, 2022.

    DOI 10.1172/JCI152341

21. Bremelanotide Injection — US Prescribing Information (DailyMed/FDA)

    DailyMed (US FDA structured product label), 2019.

    https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8c9607a2-5b57-4a59-b159-cf196deebdd9

22. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks

    FDA.

    https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks

The basis for my Oath Research recommendation is its published batch testing and stated refund-or-replacement policy for products outside specifications or purity. Its own site carries the certificate archive and service information. Part of the archive is searchable without an account; full access requires login.

These supplier records concern research-use material and service terms. I give them a separate place from the clinical papers because neither type of record can answer the other’s question. No cited clinical study is an endorsement of an Oath Research product.